Lytica Therapeutics
Lytica Therapeutics is a platform company specializing in antibody-drug conjugates (ADCs) with a focus on developing pre-clinical oncology assets. They leverage proprietary SIP technology to enhance ADC internalization and efficacy, and collaborate with biotech and pharma companies to advance antibody conjugate possibilities.
Industries
Nr. of Employees
small (1-50)
Lytica Therapeutics
Products
Preclinical ADC program — Ovarian cancer (IND-enabling)
A preclinical antibody–drug conjugate development program targeting ovarian cancer, at IND-enabling stage.
Preclinical ADC program — Multiple myeloma (development candidate selection)
A preclinical ADC program for multiple myeloma currently in development candidate selection stage.
Preclinical ADC programs — Breast and lung cancer (in vitro/in vivo POC)
Preclinical ADC programs addressing breast and lung cancer indications with in vitro and in vivo proof-of-concept studies.
Preclinical ADC program — Acute myeloid leukemia (in vitro POC)
Preclinical ADC program for acute myeloid leukemia currently at in vitro proof-of-concept stage.
Preclinical ADC program — Colorectal cancer (antibody conjugate optimization)
Preclinical ADC program for colorectal cancer focused on antibody conjugate optimization.
Preclinical ADC program — Ovarian cancer (IND-enabling)
A preclinical antibody–drug conjugate development program targeting ovarian cancer, at IND-enabling stage.
Preclinical ADC program — Multiple myeloma (development candidate selection)
A preclinical ADC program for multiple myeloma currently in development candidate selection stage.
Preclinical ADC programs — Breast and lung cancer (in vitro/in vivo POC)
Preclinical ADC programs addressing breast and lung cancer indications with in vitro and in vivo proof-of-concept studies.
Preclinical ADC program — Acute myeloid leukemia (in vitro POC)
Preclinical ADC program for acute myeloid leukemia currently at in vitro proof-of-concept stage.
Preclinical ADC program — Colorectal cancer (antibody conjugate optimization)
Preclinical ADC program for colorectal cancer focused on antibody conjugate optimization.
Services
Collaborative R&D and development partnerships to apply antibody conjugation platforms and peptide-based internalization modules to partner assets.
Collaborative R&D and development partnerships to apply antibody conjugation platforms and peptide-based internalization modules to partner assets.
Expertise Areas
- Antibody-drug conjugate (ADC) development
- Preclinical oncology development
- Antibody conjugation chemistry
- Peptide-based internalization enhancers
Key Technologies
- Antibody–drug conjugation
- Stapled peptide internalization promoters
- Linker chemistry for ADCs
- Controlled peptide-to-antibody ratio (PAR) conjugation